Problemas de Erección - No pongas excusas

• 1. Feldman HA, Goldstein I, Hatzichristou DG, y col.Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study.J Urol 1994;151: 54-61.
• 2. Lobb-Rossini K.Erectile dysfunction and its management. Journal of Community Nursing Online 1999;13 (10):1-8.
• 3. Eardley Ian, Sethia Krishna. Current Investigations and Management. Second Edition. Moby. Pág 1.
• 4. Dey J, y Shepherd MD. Evaluation and Treatment of Erectile Dysfunction in Men With Diabetes Mellitus. Mayo Clin Proc 2002; 77: 276-82.
• 5. Kirby Roger, Carson Culley, Goldstein Irwin.Erectile dysfunction. A Clinical Guide. ISIS Medical Media. Pág 25.
• 6. Un estudio de Ghezzi y colaboradores en 1995 indicó que el 44 por ciento de los hombres afectados tenían alguna dificultad sexual y el 38 por ciento tenía una disfunción eréctil total Ghezzi y col. J Neurol, 1995 242 (3):123-6.
  Alternativamente
  Hasta el 70-80% de los hombres con MS también pueden experimentar disfunción eréctil
  Eardley Ian, Sethia Krishna. Erectile Dysfunction. Current Investigations and Management. Sec-ond Edition. Moby. Pág 3.
• 7. Kirby Roger, Carson Culley, Goldstein Irwin.Erectile dysfunction. A Clinical Guide. ISIS Medical Media. Pág 25.
• 8. Kupevian V, Araujo A y col. Relative contributions of modifiable risk factors to erectile dysfunction: results from the Boston Area Community Health (BACH) Survey. Prev Med. 2010 En-Feb;50(1-2):19-25. Epub 24 Nov 2009.
• 9. Hannan JL, Maio MT y col. Beneficial impact of exercise and obesity interventions on erectile function and its risk factors. J Sex Med . Mar 2009;6 Suppl 3:254-61.
• 10. Jackson G. The importance of risk factor reduction in erectile dysfunction. Curr Urol Rep. Nov 2007;8(6):463-6.
• 11. Kupelian V, Link CL, McKinlay JB. Association between smoking, passive smoking, and erectile dysfunction: results from the Boston Area Community Health (BACH) Survey. Eur Urol. Aug 2007;52(2):416-22. Epub 16 Mar 2007.
• 12. Miller T. Diagnostic evaluation of erectile dysfunction. Am Fam Physician, 2000; 61:95-104.
• 13. Reffelmann T. Kloner RA. Sexual function in hypertensive patients receiving treatment. Vasc Health Risk Manag. 2006;2(4):447-55.
• 14. Solomon H, Man JW. Jackson G. Erectile dysfunction and the cardiovascular patient: endothelial dysfunction is the common denominator Heart. Mar 2003;89(3):251-3.
• 15. Billups KL Erectile dysfunction as a marker for vascular disease.Curr Urol Rep. Nov 2005;6(6):439-44.
• 16. Jackson G, Rosen RC y col. The Second Princeton Consensus on Sexual Dysfunction and Cardiac Risk: New Guidelines for Sexual Medicine. J Sex Med 2006; 3:28-36
• 17. Tamler R. Diabetes, obesity, and erectile dysfunction.Gend Med. 2009;6 Suppl 1:4-16.
• 18. Metabolic Syndrome.http://www.nhlbi.nih.gov/health/dci/Diseases/ms/ms_Tratamientos.html
• 19. Porst H. Premature ejaculation. Urologe A Jun 2009;48(6):663-74.
• 20. British National Formulary 58. http://bnf.org/bnf/bnf/current/
• 21. Safarinejad MR, Hosseini SY.Erectile dysfunction: clinical guidelines (2).Urol J. 2004;1(4):227-39.
• 22. Resumen Cialis sobre Características de Productos
  http://emc.medicines.org.uk/medicine/11363/SPC/Cialis+2.5mg%2c+5mg%2c+10mg+%26+20mg+film-coated+tablets/
• 23. Resumen de Viagra sobre Características de Productos
  http://emc.medicines.org.uk/medicine/1474/SPC/Viagra+25mg%2c+50mg%2c+100mg/
  
  
• 24. Resumen de Levitra sobre Características de Productos
  http://emc.medicines.org.uk/medicine/11775/SPC/Levitra+5mg%2c+10mg%2c+20mg+film-coated+tablets/
• 25. Resumen de MUSE sobre Características de Productos
  http://emc.medicines.org.uk/medicine/22218/SPC/MUSE+1000+microgram+urethral+stick./
• 26. Resumen de la Caverject Dual Chamber sobre Características de Productos
  http://emc.medicines.org.uk/medicine/21200/SPC/Caverject+Dual+Chamber+10+micrograms+%26+Caverject+Dual+Chamber+20+micrograms/
• 27. Resumen de Características de Producto de polo para inyección Caverject
  http://emc.medicines.org.uk/medicine/1480/SPC/Caverject+Powder+for+Injection+5%2c+10%2c+20%2c+40+Micrograms/
• 28. Riley A. The role of the partner in erectile dysfunction and its treatment . Int J Impot Res. 2002 Feb;14 Suppl 1:S105-9.
• 29. Aytaç, Mckinlay & Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int. 1999; 84:50-6.
• 30. Wespes E. Amar E. Eardley I y col. Guidelines of Male Sexual Dysfunction. Eur Assoc Urol. 2009. http://www.uroweb.org/fileadmin/tx_eauguidelines/2009/Full/Male_Sexual_Dysf.pdf
• 31. European Sexual Dysfunction Alliance. http://www.essm.org/patient-area/erectile_dysf.asp#q2
• 32. Caverject powder for injection Patient Information Leaflet. http://emc.medicines.org.uk/searchresults.aspx?term=caverject&searchTipo=QuickSearch
• 33. Safarinejad H. Erectile Dysfunction. Clinical Guidelines (1). Urol J, 2004, 3(1):133-147
• 34. Cancer Research UK Website – Prostate Cancer Treatment.  http://info.cancerresearchuk.org/cancerstats/Tipos/prostate/Síntomastreatment/
• 35. Physical Activity and Public health Guidelines. American College of Sports Medicine. http://www.acsm.org/AM/Template.cfm?Section=Home_Page&TEMPLATE=CM/HTMLDisplay.cfm&CONTENIDOID=7764
• 36. Banks, Ian y col.; Assessment, in a General Population of Men, of Men’s Interaction With the Healthcare System to Obtain Phosphodiesterase Tipo 5 Inhibitors; 2008; Joint Congress of the European and International Societies for Sexual Medicine
• 37. Alianza Europea para el Acceso a una Medicina Segura; La Autopista de la Falsificación; 2008
• 38. McNeil Jr., Donald G; A Growing Epidemic of Fake Medication in Asia; International Herald Tribune, 20 de Febrero, 2007